Free Trial
NASDAQ:STIM

Neuronetics (STIM) Stock Price, News & Analysis

Neuronetics logo
$1.17 +0.09 (+8.33%)
(As of 11/8/2024 ET)

About Neuronetics Stock (NASDAQ:STIM)

Key Stats

Today's Range
$1.08
$1.18
50-Day Range
$0.73
$1.19
52-Week Range
$0.66
$5.07
Volume
197,419 shs
Average Volume
246,856 shs
Market Capitalization
$35.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67
Consensus Rating
Moderate Buy

Company Overview

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
65th Percentile Overall Score

STIM MarketRank™: 

Neuronetics scored higher than 65% of companies evaluated by MarketBeat, and ranked 371st out of 974 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Neuronetics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Neuronetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neuronetics are expected to grow in the coming year, from ($0.87) to ($0.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neuronetics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neuronetics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neuronetics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Neuronetics' valuation and earnings.
  • Percentage of Shares Shorted

    2.35% of the outstanding shares of Neuronetics have been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 26.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neuronetics does not currently pay a dividend.

  • Dividend Growth

    Neuronetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.35% of the outstanding shares of Neuronetics have been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 26.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Neuronetics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Neuronetics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Neuronetics insiders have bought 7,244.65% more of their company's stock than they have sold. Specifically, they have bought $175,170.00 in company stock and sold $2,385.00 in company stock.

  • Percentage Held by Insiders

    Only 9.80% of the stock of Neuronetics is held by insiders.

  • Percentage Held by Institutions

    53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neuronetics' insider trading history.
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
BrainsWay: More Cash, More Uncertainty
See More Headlines

STIM Stock Analysis - Frequently Asked Questions

Neuronetics' stock was trading at $2.90 at the beginning of 2024. Since then, STIM stock has decreased by 59.7% and is now trading at $1.17.
View the best growth stocks for 2024 here
.

Neuronetics, Inc. (NASDAQ:STIM) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative trailing twelve-month return on equity of 109.00% and a negative net margin of 45.06%.

Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Top institutional investors of Neuronetics include GSA Capital Partners LLP (0.26%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, Stephen Furlong, Robert Cascella, William Andrew Macan, Glenn P Muir and Bruce Joseph Shook.
View institutional ownership trends
.

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), General Electric (GE), Intel (INTC), Bank of America (BAC) and Nokia Oyj (NOK).

Company Calendar

Last Earnings
8/12/2024
Today
11/08/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:STIM
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+300.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-30,190,000.00
Pretax Margin
-45.06%

Debt

Sales & Book Value

Annual Sales
$71.35 million
Book Value
$1.18 per share

Miscellaneous

Free Float
27,337,000
Market Cap
$35.31 million
Optionable
Optionable
Beta
2.21
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:STIM) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners